Quinolones Market Report

To learn more about this report, Download Free Sample Report

Global Quinolones Market Size

The global quinolones market size was valued at USD 52.64 billion in 2025 and is expected to reach USD 75.37 billion by 2034 from USD 54.78 billion in 2026. The market is growing at a CAGR of 4.07% during the forecast period.

Quinolones are a type of antibacterial medication. Quinolones and fluoroquinolones are antibacterial medicines with the unique effect of blocking nucleic acid production. Quinolones are effective against bacterial infections of the skin, sinuses, lungs, stomach, and urinary tract, depending on their bactericidal characteristics. These medications can interfere with human DNA synthesis due to their ability to suppress nucleic acid synthesis, as humans have the same fundamental nucleic acid contents as bacteria. Quinolones have a fast bactericidal effect, as they quickly permeate the bacterial cell membrane and reach the DNA, where they bind to bacterial topoisomerases such as DNA gyrase, blocking their function and thereby inhibiting the bacterial nucleic acid synthesis. Macrolides, tetracyclines, aminoglycosides, sulfonamides, phenicols, quinolones, and other antibacterial medications are the different types of antibacterial pharmaceuticals. These characteristics further increases the Quinolones Market share in the next six years. A quinolone antibiotic is a broad-spectrum bactericide having the chemical 4-quinolone as its basic structure. Quinolones are antibiotics used in veterinary and human medicine, as well as animal husbandry, to treat bacterial infections.

Due to increased competition, the quinolones market is expected to display significant growth potential throughout the forecast period. In the worldwide quinolones market, new rivals are giving a variety of solutions at reasonable prices to meet the need for quinolones, making them more accessible to customers.

MARKET DRIVERS

The rising prevalence of infectious diseases caused by the introduction of diverse mutant bacterial strains around the world is a major driver for the quinolones/fluoroquinolones industry. Other factors include the rising prevalence of multidrug-resistant microorganisms, which raises healthcare concerns while also providing sufficient growth prospects for pharmaceutical companies. Quinolones may partially replace other pharmacological therapy due to their significant advantages over other antibacterial medicines. Good oral absorption, faster tissue penetration, lesser side effects, easy once or twice-daily dose, and broad-spectrum action against various dangerous bacterial strains are among these positive properties. The quinolones market is also growing due to an increase in the prevalence rate of infectious diseases worldwide, as well as the incidence of indoor and outdoor infections. Nutrition, immunization, antibiotics, and other healthcare drugs are all improving, which is propelling the quinolones market forward. Furthermore, as the demand for innovative therapeutics has grown significantly, it has made a substantial contribution to the worldwide market growth of quinolones.

MARKET RESTRAINTS

Effective treatments, on the other hand, are either not widely available or are extremely expensive for most people, limiting market expansion. Furthermore, the advent of generic medications and the expiration of patents from diverse companies, a limited development pipeline, and the availability of several generic drugs are projected to limit the market growth. Additionally, the lack of qualified employees and severe safety standards are further impeding industry expansion of quinolones.Certain uncommon side effects include muscle, bone, tendon, and nervous system impairment. This constraint may limit the increase of quinolones’ market share in the future while potentially reducing quinolone sales in the present. As a result, many quinolone producers are leaving the Quinolones Market posing a serious threat to the growth of the overall Quinolones industry.

REPORT COVERAGE

Quinolones Market Segmentation: 

By Product Type:

• Norfloxacin 

• Ofloxacin 

• Ciprofloxacin 

• Gemifloxacin 

• Others

Based on the product type, the Quinolones Market can be segregated into five categories. They are Norfloxacin, Ofloxacin, Ciprofloxacin, Gemifloxacin and Others. Norfloxacin dominates the market share owing to the fast bactericidal effect that inhibits bacterial deoxyribonucleic acid production (DNA). DNA gyrase, an enzyme, is important in this process. It, on the other hand, shows antibacterial activity against both gram-positive and gram-negative aerobic bacteria throughout a broad spectrum.

By Form:

• Tablets

• Capsules

• Liquid

Based on form, the Quinolones Market can be bifurcated into Tablets, Capsules and Liquids. Because of its stability and patient acceptability, the tablet is the most extensively utilised dosage form. Film and sugar coatings are used to improve aesthetic qualities such as colour, texture, mouthfeel, and taste masking, hence the coating is an important aspect of the tablet composition.

REGIONAL ANALYSIS

• North America

In the worldwide Quinolones Market, North America presently have significant demand for quinolones. The antibiotics industry is expanding in North America, mainly to the high prevalence of infectious diseases and the rapid introduction of generic medications. As a result, the rising incidence of drug-resistant bacteria forces manufacturers and R&D institutions to develop new antimicrobial variations that are effective against both new and old bacterial strains, boosting the antibiotics industry.

• The Asia Pacific

The rising prevalence of infectious diseases in underdeveloped countries presents enormous potential opportunities for the Quinolones Market in APAC.

• Europe

Due to increased demand for broad-spectrum bactericidal activity new generation quinolones, great oral bioavailability, good tissue penetration, and improved safety and tolerability, quinolones are expected to expand at the quickest rate among European antibiotics throughout the projection period.

• Middle East & Africa

• Latin America

KEY MARKET PLAYERS

1. Bayer AG

2. Novartis AG.

3. Sanofi

4. Johnson & Johnson

5. Merck & Co, Inc.

6. LG Life Sciences

7. Allergan, Inc.

RECENT HAPPENINGS IN THE MARKET

• Baxdela (delafloxacin) was introduced by Melinta Therapeutics, Inc. recently. Adult patients with susceptible bacterial acute bacterial skin and skin structure infections are treated with Baxdela, an oral fluoroquinolone (ABSSSI). The development of Baxdela gives a new therapy option and boosts the company's growth in the infection therapies market.

• Lasvic (lascufloxacin hydrochloride), a new quinolone antibacterial agent suggested as a first-line monotherapy for the treatment of community-acquired respiratory and ENT infections, was licenced by the Japanese Ministry of Health, Labor, and Welfare in September 2019. The approval of Lasvic is a significant step forward in the company's efforts to tackle antimicrobial resistance and provide patients with adequate treatment options.